LEADER 03960nam  2200625 a 450 
001 9910781782503321
005 20230725050930.0
010   $a0-309-21224-3
010   $a1-283-21345-1
010   $a9786613213457
010   $a0-309-21222-7
035   $a(CKB)2550000000043073
035   $a(EBL)3378800
035   $a(SSID)ssj0000537170
035   $a(PQKBManifestationID)11352570
035   $a(PQKBTitleCode)TC0000537170
035   $a(PQKBWorkID)10553842
035   $a(PQKB)11052430
035   $a(MiAaPQ)EBC3378800
035   $a(Au-PeEL)EBL3378800
035   $a(CaPaEBR)ebr10488621
035   $a(CaONFJC)MIL321345
035   $a(OCoLC)923283605
035   $a(EXLCZ)992550000000043073
100   $a20110827d2011      uy             0
101 0 $aeng
135   $aurcn|||||||||
181   $ctxt
182   $cc
183   $acr
200 10$aGlutamate-related biomarkers in drug development for disorders of the nervous system$b[electronic resource] $eworkshop summary /$fDiana E. Pankevich, Miriam Davis, and Bruce M. Altevogt, rapporteurs ; Forum on Neuroscience and Nervous System Disorders, Board of Population Health and Public Health Practice, Institute of Medicine of the National Academies
210   $aWashington, D.C. $cNational Academies Press$d2011
215   $a1 online resource (74 p.)
300   $aDescription based upon print version of record.
311   $a0-309-21221-9 
320   $aIncludes bibliographical references and index.
327   $a""Front Matter""; ""Reviewers""; ""Contents""; ""1 Introduction""; ""2 Overview of the Glutamatergic System""; ""3 Glutamate Biomarkers""; ""4 Treatment Implications of Biomarkers""; ""5 Challenges and Opportunities""; ""Appendix A: References""; ""Appendix B: Registered Attendees""; ""Appendix C: Agenda""
330   $aGlutamate is the most pervasive neurotransmitter in the central nervous system (CNS). Despite this fact, no validated biological markers, or biomarkers, currently exist for measuring glutamate pathology in CNS disorders or injuries. Glutamate dysfunction has been associated with an extensive range of nervous system diseases and disorders. Problems with how the neurotransmitter glutamate functions in the brain have been linked to a wide variety of disorders, including schizophrenia, Alzheimer's, substance abuse, and traumatic brain injury. These conditions are widespread, affecting a large portion of the United States population, and remain difficult to treat.  Efforts to understand, treat, and prevent glutamate-related disorders can be aided by the identification of valid biomarkers. The Institute of Medicine's Forum on Neuroscience and Nervous System Disorders held a workshop on June 21-22, 2010, to explore ways to accelerate the development, validation, and implementation of such biomarkers. This book investigates promising current and emerging technologies, and outlines strategies to procure resources and tools to advance drug development for associated nervous system disorders. Moreover, this report highlights presentations by expert panelists, and the open panel discussions that occurred during the workshop.
606   $aGlutamic acid$xPharmacokinetics
606   $aCentral nervous system$xDiseases
615  0$aGlutamic acid$xPharmacokinetics.
615  0$aCentral nervous system$xDiseases.
676   $a616.8061
701   $aPankevich$b Diana E$01521289
701   $aDavis$b Miriam$0856948
701   $aAltevogt$b Bruce M$01478507
712 02$aInstitute of Medicine (U.S.).$bForum on Neuroscience and Nervous System Disorders.
712 02$aInstitute of Medicine (U.S.).$bBoard of Population Health and Public Health Practice.
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910781782503321
996   $aGlutamate-related biomarkers in drug development for disorders of the nervous system$93760324
997   $aUNINA